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Glucose intolerance, hyperinsulinemia, peripheral in-
sulin resistance and hyperglucagonemia are common in 
patients with advanced liver disease. These abnormali-
ties in the plasma levels of the pancreatic hormones, 
insulin and glucagon have been thought to be responsi-
ble, at least in part, for the abnormal plasma ratio of 
branched-chain amino acids to aromatic amino acids. To 
evaluate this issue, plasma levels of glucose, insulin, 
glucagon, C-peptide and the branched-chain and aro-
matic amino acids were measured before and serially 
after orthotopic liver transplantation in 9 humans and 
5 dogs. The abnormal plasma amino acid levels rapidly 
improved and achieved normal levels following ortho-
topic liver transplantation. Insuiin levels also became 
normal following orthotopic liver transplantation, de-
spite enhanced insulin secretion documented by an even 
further increased level of C-peptide. In contrast, the 
baseline abnormal plasma glucagon levels which are 
commonly seen in cirrhotics became even more abnor-
mal following orthotopic liver transplantation. Despite 
this progressive increase in the abnormally elevated 
plasma glucagon levels, plasma amino acid levels, both 
branched-chain and aromatic, became normal. These 
data demonstrate that before and after orthotopic liver 
transplantation, there is: (i) no relationship between the 
changes in plasma levels of glucagon and changes ob-
served in the plasma level of amino acids; and (ii) plasma 
insulin and amino acid levels change in the same direc-
tion. In addition, these changes in plasma insulin and 
amino acid levels following orthotopic liver transplan-
tation occur despite enhanced secretion of insulin evi-
denced by the progressive increase in plasma levels of 
C-peptide. 
Glucose intolerance (1, 2), hyperinsulinemia (3, 4), 
insulin-resistance (5, 6) and hyperglucagonemia (7-9) 
are common in patients with advanced liver disease. 
These hormonal abnormalities are thought to either con-
tribute to or be responsible for the reduced plasma con-
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centrations of the three principal branched-chain amino 
acids (BCAAs) valine, leucine and isoleucine, that are 
characteristic of endstage liver disease. As a result, these 
same hormonal abnormalities are thought also to con-
tribute to the decreased molar ratio that exists in plasma 
between the BCAAs and the aromatic amino acids 
(AAAs) tyrosine, phenylalanine and tryptophan in cir-
rhotics (10-13). Herein, we report our observations con-
cerning the plasma levels of insulin and glucagon and 
the major amino acids before and after orthotopic liver 
transplantation. The changes observed occur in cirrhot-
ics postoperatively, were compared to those observed to 
occur in a noncirrhotic human recipient with normal 
liver function, who underwent liver transplantation for 
multiple hepatic adenomatosis and were also compared 
to those observed in five normal dogs, which were sub-
mitted to liver replacement under controlled laboratory 
conditions. 
MATERIALS AND METHODS 
Case Material. The clinical and physical characteristics 
of the eight cirrhotic patients and the single individual with 
multiple hepatic adenomatosis studied are shown in Table 1. 
As can be seen from the table, the patient with multiple hepatic 
adenomatosis had normal liver function. In contrast, the cir-
rhotic patients all had liver dysfunction as documented by the 
abnormalities in their bilirubin, prothrombin time and albumin 
levels. All patients were ingesting a 50 to 60 gm per day protein 
diet during the study when eating (preoperatively and after the 
fourth postoperative day). This intake is more than sufficient 
to guarantee adequate nutrition for all but the largest of indi-
viduals, particularly considering the inactivity and decondition-
ing present universally in the patients studied. 
Cyclosporine and prednisone were used as the immunosup-
pressive agents for all of the recipients studied (14, 15). The 
preoperative, intraoperative and postoperative requirements for 
blood utilized by the patients studied are shown in Table 2. 
The five mongrel dogs transplanted and studied weighed 
between 15 to 20 kg and, like the humans studied, were given 
cyclosporine and prednisone to prevent rejection using doses 
that, on a milligram per kilogram basis, were similar to those 
used by the patients (16). The surgical procedures used for the 
patients and animals were identical (15, 16). 
Special Analyses. The plasma levels of immunoreactive 
insulin (lRI) were determined by radioimmunoassay using an 
insulin kit obtained from Serono Diagnostics (Braintree, 
Mass.). The detection limit of the assay was 5 IlU per ml. The 
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TABLE 1. Patients treated with OL Tx 
Name Sex Age Diagnosis Bilirubin Prothrombin Albumin Height Weight (yr) (mg/lOO ml) time (sec) (gm/dl) (inches) (kg) 
B. R. M 18 CAR 38.8 18 2.7 69 55 
R.Y. F 25 CAR 9.9 15 2.6 64 63 
T.H. F 23 CAR 2.2 16 2.2 64 61 
G.R. M 37 SC 19.7 15 2.6 62 92 
S. J. F 41 SC 15.3 14 2.9 69 62 
K. D. M 34 SC 23.7 14 2.8 68 75 
S. R. F 29 Wilson's disease 3.5 17 2.7 66 69 
S.P. F 43 AD 4.9 14 2.8 65 61 
G.B. F 29 Hepatic adenoma 0.5 13 3.0 
Clinical characteristics, bilirubin, prothrombin time, albumin levels, height and weight of the eight cirrhotic patients and the single patient 
with multiple adenomatosis are indicated. CAH = chronic active hepatitis; SC = sclerosing cholangitis; AD = ar-antitrypsin deficiency; OLTx = 
orthotopic liver transplantation. 
TABLE 2. Units of blood used by the patients studied 
Patient Preoperative Intraoperative Postoperative 
B. R. 26 22 8 
R. Y. 18 8 3 
T.R. 5 6 5 
G.R. 9 14 16 
S. J. 4 18 0 
K.D. 4 11 3 
S. R. 5 13 60 
S. P. 19 7 2 
G.B. 0 5 2 
coefficient of variation for replicate samples assayed in our 
laboratory with this test is 8.37%. The plasma levels of C-
peptide were determined by radioimmunoassay using a C-
peptide kit obtained from Serono Diagnostics. The detection 
limit of the assay was 0.2 ng per ml. The coefficient of variation 
for replicate samples assayed in our laboratory with this test is 
6.5%. 
The plasma levels of immunoreactive glucagon (IRG) were 
determined with a glucagon kit also obtained from Serono 
Diagnostics. This kit was chosen specifically because of its high 
degree of accuracy, precision and specificity, as has been re-
ported by Kenny and Say (17). Samples for the glucagon assay 
were collected in chilled tubes containing 500 units of a trypsin 
inhibitor (aprotinin) and 1.2 mg sodium EDT A per ml of whole 
blood collected for assay. The detection limit for the assay was 
15 pg per ml. The coefficient of variation for this kit in our 
laboratory assaying replicate samples is 9.6%. 
Representative samples of control sera were assayed for 
insulin, glucagon and C-peptide with and without cyclosporine 
added to the sample to achieve concentrations of cyclosporine 
found in blood clinically. No systemic difference was noted in 
the results. Moreover, all results were within the limits for 
variability for identical samples run in duplicate (Table 3). 
For representative blood samples obtained from each patient 
studied, both before and after transplantation, a gel filtration 
technique (18) was used to determine the amount of IRG-
detectable glucagon having molecular weights of 3,500, 7,000 
and 40,000 daltons. Insulin/glucagon molar ratios were calcu-
lated as suggested by Muller et al. (19) using the formula: 
[IRI (/1 U per ml) /IRG (pg per ml) 1 x 23.33 = ratio 
This formula assumes that insulin has a molecular weight of 
6,000 daltons and a biologic activity of 25 units per mg. It also 
assumes that glucagon has a molecular weight of 3,500 daltons. 
TABLE 3. Replicate control samples (n = 20) assayed for their 
hormone content in the presence and absence of added 
cyclosporine at a concentration of 1,000 mg/ml whole blood 
Hormone Cyclosporine (-) Cyclosporine (+) 
Insulin (ltD/mil 17.0 ± 6.8 18.5 ± 5.9 
Glucagon (pg/ml) 167 ± 61 158 ± 67 
C-peptide (ng/ml) 1.36 ± 0.777 1.29 ± 0.84 
Amino acid profiles were determined on deproteinized sam-
ples of plasma treated with 4% sulfosalicylic acid. The resultant 
supernatants were applied to an amino acid analyzer (Beckman 
Instruments, Somerset, NJ) and the levels of free BCAAs and 
AAAs, including tryptophan, were determined. As was done 
with the hormone assays, representative duplicate control blood 
samples were assayed for their amino acid content in the 
presence and absence of added cyclosporine to achieve levels 
seen in patients following transplantation. No consistent dif-
ference was noted between such duplicate samples, and all such 
samples assayed provided results within the range expected for 
replicate identical samples (data not shown). The glucose de-
terminations were made using a glucose-oxidase method (20). 
Statistical Analysis. The unpaired Student's t test was 
used for statistical analysis of the data. A p value < 0.05 was 
considered to be significant. 
RESULTS 
Endstage Liver Disease 
Insulin and C-Peptide Levels: Because blood trans-
fusions can alter hormone and amino acid levels, the 
blood requirements for the patients studied are shown in 
Table 2. In the eight patients studied, the C-peptide 
plasma concentrations were all high-normal preopera-
tively and rose 21J2-fold during the first 12-hr following 
liver transplantation to a maximum level of 10 ng per ml 
and remaining elevated for at least 30 days (Figure 1A). 
The plasma IRI levels followed a somewhat different 
pattern (Figure IB). Following transplantation, there 
was a 2-fold increase in the IRI levels, but this increase 
lasted for only a few hours and subsequently returned to 
near-normal levels at 4 days posttransplantation. Be-
cause of these quite different patterns, there was a rapid 
increase in the C-peptide/IRI (Figure lC), which reached 
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a maximum at 4 days and remained elevated throughout 
the 30-day study period. When reexamined at 6 months, 
both the insulin and C-peptide plasma levels were still 
slightly elevated (Table 4). 
Glucagon: Before operation, the plasma levels of IRG 
were 4 times the normal values (Table 4). After trans-
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FIG. 1. Plasma C-peptide, insulin and C-peptide/insulin molar ratio 
levels in the eight patients before and after orthotopic liver transplan-
tation (OL Tx). The preoperative determinations were made at least 3 
times in each patient. The points represent mean values. The brackets 
represent the S.D. All points after the zero in (A) except the 20- and 
25-hr time points are different than the preoperative values, with a p 
value < 0.025. All points in (C) after time zero differ from those 
obtained preoperatively, with a p value of < 0.005. 
plantation, the IRG level rose progressively. The highest 
mean plasma levels of IRG were found at 30 days follow-
ing transplantation (Figure 2), but when restudied at 6 
months had returned to the normal range (Table 4). The 
resultant IRIjIRG molar ratio was decreased further 
than that determined preoperatively, as a consequence 
of the observed hyperglucagonemia. However, 6 months 
after transplantation, the IRIjIRG reached the highest 
levels as a result of persistent hyperinsulinemia and 
normalization of glucagon levels. 
The gel filtration studies demonstrated that the hy-
perglucagonemia, both before and after transplantation, 
was predominantly due to the presence of IRG having a 
molecular weight of 3,500 daltons. This form of the 
hormone is thought to be the most biologically active 
fraction (21). Figure 3 reports a sharp increase of plasma 
glucose levels probably related to the intense glucocorti-
coid therapy used during the first days following trans-
plantation. Blood glucose levels returned to the normal 
range 6 days after operation and remained normal during 
all of the observation period. 
Amino Acids: The preoperative elevations of AAAs 
(Figure 4C) and the depressed levels of BCAAs (Figure 
4B) returned to the normal range for each within 12 hr 
after transplantation. More importantly, the plasma 
amino acid levels and the BCAAj AAA ratio (Figure 4A) 
subsequently achieved the normal range for the entire 
30-day study period. 
Control Study: No changes were observed in the nor-
mal levels of IRI, IRG and C-peptide levels following 
liver transplantation in the one patient with multiple 
hepatic adenomatosis studied (Figure 5A). Similarly, no 
changes were observed for these same substances in the 
five normal dogs submitted to liver transplantation (Fig-
ure 5B). However, this individual and these dogs had no 
abnormalities preoperatively that might otherwise have 
been expected to correct following successful transplan-
tation. Importantly these data suggest that neither the 
doses of prednisone used nor the cyclosporine used to 
prevent rejection contributed to the hormonal and amino 
acid findings observed in the cirrhotic patients studied. 
TABLE 4. Levels of glucagon, insulin, C-peptide and IRI/IRG molar ratio 
Total glucagon Glucagon Insulin C-Peptide IRI/IRG n (pg/ml) (pg/ml) (fJV/mI) (ng/ml) 
Normal subjects 10 90 ± 15 75 ± 16 20 ± 5 3.2 ± 0.5 3.3 ± 0.3 
Cirrhotic patients 
Before OLTx 8 350 ± 60 294 ± 51 25 ± 5 4 ± 0.5 1.5 ± 0.5 
p < 0.05 p < 0.05 NS NS p < 0.01 
30 days after OL Tx 8 750 ± 110 638 ± 87 22 ± 8 6±1 0.6 ± 0.1 
p < 0.01 p < 0.01 NS p < 0.01 p < 0.001 
180 days after OL Tx 8 80 ± 12 68 ± 9 30 ± 7.15 3.8 ± 0.5 10.2 ± 1 
NS NS p < 0.05 NS p < 0.001 
Levels of glucagon, C-peptide, insulin and IRI/IRG ratio in normal subjects, and in eight cirrhotic patients who underwent liver transplantation. 
The determinations in the operated patients were made before transplantation, 30 days and 180 days after transplantation. The data for "normal 
subjects" refer to determinations obtained in 10 healthy people age 18 to 45 yr. Each value is expressed as mean ± S.D. Significance (p) is in 
relation to the values of normal subjects. Molecular weight of glucagon was 3,500 daltons. OL Tx = orthotopic liver transplantation; NS = not 
statistically significant. 
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FIG. 2. Plasma glucagon in the eight 
patients before and after orthotopic liver 
transplantation (OLTx). Each value is 
expressed as mean ± S.D. Asterisk de-
notes a p < 0.05 value compared to the 
value determined preoperatively. 
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FIG. 3. Plasma glucose in the eight patients before and after ortho-
topic liver transplantation. Each value is expressed as mean ± S.D. 
Asterisk denotes a p < 0.05 value for the level denoted as compared to 
the preoperatively determined level. 
DISCUSSION 
The purpose of this study was to determine if the 
hormonal abnormalities which are characteristic of end-
stage chronic liver disease can be corrected by orthotopic 
liver transplantation, and if so, how quickly. The evi-
dence that has emerged is both conclusive and provoca-
tive. Both the hyperinsulinemia and the hyperglucago-
nemia evident preoperatively persisted for some time 
after successful transplantation, suggesting that the hy-
persecretion of these two hormones which characterizes 
chronic liver disease was not promptly corrected with 
elimination of the liver disease per se. Although the 
plasma insulin level gradually returned to the normal 
range within several days of the transplant procedure, 
the plasma glucagon level continued to be abnormally 
elevated and in fact became progressively more abnormal 
(more elevated) for several weeks before it also became 
normal sometime between 1 and 6 months postopera-
tively. These data, coupled with the data obtained from 
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a patient with multiple hepatic adenoma but normal liver 
function, suggest that the abnormalities seen in the 
patients with advanced liver disease reflected alterations 
in hormone balance and energy metabolism, which were 
due to the individual's advanced liver disease and not to 
the surgical procedure and the immunotherapy that fol-
lowed the procedure. These observations also support 
the prior findings of Sherwin et al. (7, 8) and Dudley et 
al. (21) that suggest that overproduction of the pancreatic 
hormones rather than defective hepatic uptake accounts 
for the hyperglucagonemia and hyperinsulinemia of ad-
vanced liver disease. Even more importantly, failure to 
demonstrate any relationship between the changes in the 
plasma levels of glucagon and either the BCAAs or AAAs 
in these studies suggests that the abnormal plasma levels 
of both classes of amino acids present in patients with 
liver disease are not regulated or determined to a major 
degree by the hyperglucagonemia present in patients 
with advanced liver disease. Conversely, these data sug-
gest that the elevated plasma levels of glucagon seen in 
advanced liver disease play little or no role in the pro-
duction or maintenance of the abnormal plasma amino 
acid levels seen in patients with advanced liver disease. 
The rather abrupt increases observed in plasma glu-
cagon levels and insulin secretion documented by the 
increased C-peptide levels observed in the early postop-
erative period may represent homeostatic regenerative 
signals associated with or due to the transplantation 
procedure per se and the expected loss of hepatocytes 
that occurs due to unavoidable graft ischemia (occurring 
during organ harvesting) and mild to moderate rejection 
that are also a consequence of the procedure. 
In contrast to the observations for plasma glucagon, 
plasma insulin levels returned to near-normal range 
within days of the transplant procedure, despite apparent 
persistent hypersecretion of the hormone documented by 
the increased plasma level of C-peptide and a progressive 
rise in the C-peptide/insulin ratio. This apparent in-
crease in insulin secretion was independent of the tran-
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sient increase of glucose observed during the first 6 days 
after transplantation and is well beyond the period of 
increased blood glucose seen postoperatively. These data 
suggest that the transplanted liver actively removes se-
creted insulin from the portal circulation, thereby main-
taining a normal systemic plasma level of the hormone 
despite excess production and secretion of the hormone 
by the pancreas. It should be noted, however, that several 
recent studies have suggested that cyclosporine inhibits 
insulin synthesis and secretion by the pancreas (22-24). 
Moreover, as the renal function of the patients and the 
animals studied did not become impaired (data not 
shown), it is most unlikely that these changes reflect an 
alteration in renal handling or clearance of either C-
peptide or insulin. Nonetheless, it is at least theoretically 
possible that the increased C-peptide levels reflect cyclo-
sporine nephrotoxicity not apparent from the serial cre-
atinine or blood urea nitrogen determinations made 
throughout the study. 
The changes in the plasma levels of insulin and glu-
cagon seen in the eight patients with advanced chronic 
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FIG. 4. BCAAj AAA molar ratio and 
BCAA and AAA levels in the eight pa-
tients before and after orthotopic liver 
transplantation (OL Tx). The preopera-
tive determinations were made at least 3 
times in each patient. Each value is ex-
pressed as mean ± S.D. The shaded area 
represents the range of values for normal 
individuals. 
liver disease, who were studied, were not seen in the one 
patient with normal hepatic function and multiple he-
patic adenomatosis studied or in the five normal dogs 
that were transplanted experimentally. Thus, the hor-
monal changes observed in the patients with advanced 
liver disease would appear to be specific for liver disease 
per se and not the transplant procedure or the immuno-
suppressive regimen used. 
Relevant to this point, it should be remembered that, 
as a direct consequence of the liver transplantation pro-
cedure for endstage liver disease, that the portosystemic 
collaterals that have developed between the viscera and 
the systemic circulation, as a result of the associated 
portal hypertension present in such patients preopera-
tively, are destroyed. Such shunts have been suggested 
to be the route by which plasma glucagon levels are 
increased in patients with advanced liver disease (7, 19). 
Our data would provide rather strong support against 
such a possibility, in that following the destruction of 
most, if not all, of these shunts during the operative 
procedure, the systemic plasma level of glucagon in-
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FIG. 5. Insulin, C-peptide and gluca-
gon levels in a noncirrhotic patient who 
received orthotopic liver transplantation 
(OL Tx) for multiple hepatic adenomas 
(A) and in five normal dogs before and 
after liver replacement (B). Each value 
is expressed as mean ± S.D. Asterisk 
denotes a p < 0.05 value as compared to 
the value observed preoperatively. 
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creased even further. In contrast, the present data sug-
gest, but do not prove, that hypersecretion and not 
hepatic circulatory bypass via collateral vessels accounts 
for the hyperglucagonemia seen in cases of advanced 
chronic liver disease. 
Furthermore, in contrast to current popular opinion 
which suggests that the hyperglucagonemia of chronic 
liver disease accounts for the reduced plasma levels of 
the BCAAs relative to those for the AAAs seen in indi-
viduals with liver disease, the present data suggest that 
such is not the case. Specifically, despite persistent and, 
in fact, worsening hyperglucagonemia, the plasma amino 
acid levels rapidly returned to normal following success-
ful transplantation. This normalization of the plasma 
amino acid levels was similar to, and occurred in concert 
with, the changes observed for plasma insulin. These 
data are consistent with the recent suggestion that the 
reduced BCAA levels seen in cases of advanced cirrhosis 
are due to the increased plasma levels of insulin seen in 
such individuals. It has been proposed by the authors of 
this latter hypothesis that the systemic hyperinsulinemia 
of advanced chronic liver disease drives plasma BCAA 
into adipocytes, thereby producing an abnormal reduc-
tion in the plasma level of the BCAAs, which is charac-
teristic of cirrhosis (13). The current observations that 
the plasma levels of the BCAAs normalize concurrently 
with the plasma levels of insulin provides strong, albeit 
indirect, support for this hypothesis. Equally important, 
however, is the observation that the plasma level of 
BCAAs normalize while the plasma glucagon level be-
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comes progressively more abnormal. This suggests that 
the plasma levels of glucagon do not regulate the plasma 
level of the BCAAs. 
Many investigators have reported reduced insulin sen-
sitivity in cirrhotics being defined in terms of the ob-
served reduction in plasma glucose and glucose utiliza-
tion as well as reduced plasma levels of BCAAs in re-
sponse to exogenous insulin infusions (26-29). It is of 
some interest that similar results have been obtained 
under conditions of euglycemia and uncontrolled glucose 
concentrations. Although these data clearly demonstrate 
end organ hyporesponsiveness to insulin, they by no 
means demonstrate that insulin alone regulates the 
plasma concentration of the BCAAs in either normal or 
cirrhotic individuals. Specifically, they demonstrate just 
the opposite; i.e., although insulin exerts some control 
over the plasma level of BCAAs as a result of its ability 
to enhance BCAA entry into muscle, this control has 
only a moderate effect at best upon the measured plasma 
level of the BCAAs (28). 
In contrast to the complex factors that appear to 
control the plasma levels of the BCAAs, the changes 
observed in the AAAs in patients with liver disease are 
more clearly explained as being due solely to a reduced 
hepatic clearance of these amino acids (30). With re-
placement of the diseased liver with a normal liver, the 
plasma level of the AAAs returns to normal. 
Finally, the present study demonstrates that studies 
such as this can provide important insight, not otherwise 
obtainable, to a better understanding of some of the 
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metabolic abnormalities that accompany chronic ad-
vanced liver disease. It also needs to be stated, however, 
that any attempt to correlate the blood levels of different 
metabolic substances is precarious and that any such 
relationship, when found, need not be causal. Nonethe-
less, these data suggest that, by monitoring the plasma 
levels of certain hormones, particularly insulin, and the 
plasma levels of various amino acids, and the ratio of the 
BCAAs to the AAAs, information concerning graft func-
tion in the very early postoperative period can be ob-
tained which can be used by transplant surgeons when 
the more usually obtained parameters of hepatic injury 
and/or function are more difficult to interpret, as a 
consequence of the transplant procedure itself. Early 
reports confirming this suggestion have already been 
reported by Reilly et a1. (31), Fath et a1. (32) and Pearly 
et a1. (33). 
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